IL1B and infection: However, their overall efficacy lags behind JAK inhibitors (notably in ACR20/70 responses), and safety concerns—including higher rates of severe adverse events and treatment discontinuation—may relate to suppression of IL-1β’s broad physiological roles (e.g., infection defense).